<DOC>
	<DOCNO>NCT02564666</DOCNO>
	<brief_summary>Sorafenib oral multikinase inhibitor antiproliferative antiangiogenic effect use systemic treatment patient unresectable hepatocellular carcinoma . Although sorafenib demonstrate many clinical benefit patient , adverse ignores . This drug occasionally cause severe adverse event ( AEs ) , include hand-foot skin reaction ( HFSR ) , hypertension , diarrhea , anorexia , fatigue , weight loss , . Although adverse event reversible , significantly impact patient 's quality life occasionally result dose reduction discontinuation therapy Patients also likely remain treatment guide difficult initial 4~6wks therapy time development adverse event follow sorafenib treatment initiation likely occur . Patient education , proactive management establish maintain open communication patient nurse crucial effective management adverse event . This study design randomize control trial 64 patient randomize one 2 group 1:1 ratio . 32 patient enrol control group rest 32 patient enrolled intervention group . The intervention group receive routine telephone call six time interval week 10~15 minute ( well-trained nurse ) The purpose study confirm whether effective intervention telephone counsel education nurse increase drug compliance patient HCC take Sorafenib use develop individual educational program fundamental data apply patient take Sorafenib investigate patient satisfaction `` The Satisfaction information Medicines Scale ( SIMS ) '' tool .</brief_summary>
	<brief_title>The Effect Telephone Counseling Compliance Satisfaction Advanced HCC Patients Receiving Sorafenib</brief_title>
	<detailed_description>This study design randomize control trial 64 patient randomize one 2 group 1:1 ratio . 32 patient enrol control group rest 32 patient enrolled intervention group . The intervention group receive routine telephone call six time interval week 10~15 minute ( well-trained nurse ) The purpose study confirm whether effective intervention telephone counsel education nurse increase drug compliance patient HCC take Sorafenib use develop individual educational program fundamental data apply patient take Sorafenib investigate patient satisfaction `` The Satisfaction information Medicines Scale ( SIMS ) '' tool .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patient agree voluntarily Patient diagnosis HCC receive Sorafenib monotherapy . ChildPugh class , A B , ECOG PS 0~2 20 year age old . Patient listen speak Korean lack cognitive ability r psychiatric illness Patient receive combination treatment TACE HCC treatment Sorafenib . A hearingimpaired patient . Patient accompany primary malignants tumor organ except HCC .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>telephone counseling</keyword>
</DOC>